Tempus AI inks Merck partnership and $95 price target with 82.6% upside
Tempus AI Inc. secured a multi-year collaboration with Merck to use its Lens Platform and GPU infrastructure for precision medicine biomarker discovery, targeting oncology resistance mechanisms. H.C. Wainwright analyst Yi Chen raised the price target to $95, implying an 82.6% upside from the current ~$52 share price.
1. Analyst Raises Price Target to $95
Yi Chen from H.C. Wainwright set a $95 target on Tempus AI shares, implying an 82.6% potential gain from the prevailing ~$52 price level. This forecast reflects confidence in Tempus’ AI-driven precision medicine platform and its growth prospects.
2. Multi-Year Merck Collaboration
Tempus AI entered a strategic agreement with Merck to apply its Lens Platform and one of the industry’s largest GPU infrastructures to identify novel precision medicine biomarkers. The partnership aims to enhance oncology research by uncovering resistance mechanisms and accelerating drug development.
3. Market Reaction and Valuation Metrics
Following the announcement, Tempus AI shares traded around $51.85 with intraday fluctuations between $51.73 and $52.93. The company’s market capitalization stands at approximately $8.96 billion with daily volume near 928,414 shares, and a 52-week range of $36.22 to $104.32.